NanoViricides Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de NanoViricides de 7.8% y 72.9% respectivamente, mientras que el BPA crecerá en un 16.1% al año.

Información clave

7.8%

Tasa de crecimiento de los beneficios

16.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	63.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

Feb 18

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:NNVC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2027	7	-6	-4	-4	1
6/30/2026	3	-8	-5	-5	1
6/30/2025	N/A	-11	-9	-8	2
6/30/2024	N/A	-7	-6	-6	2
3/31/2024	N/A	-10	-6	-6	N/A
12/31/2023	N/A	-9	-6	-6	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-9	-6	-6	N/A
3/31/2023	N/A	-7	-6	-6	N/A
12/31/2022	N/A	-7	-6	-5	N/A
9/30/2022	N/A	-7	-7	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-9	-7	-7	N/A
6/30/2021	N/A	-9	-8	-8	N/A
3/31/2021	N/A	-9	-8	-8	N/A
12/31/2020	N/A	-15	-9	-9	N/A
9/30/2020	N/A	-14	-8	-7	N/A
6/30/2020	N/A	-13	-7	-7	N/A
3/31/2020	N/A	-14	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-8	-7	-7	N/A
3/31/2019	N/A	-8	-9	-9	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-9	-8	-8	N/A
3/31/2018	N/A	-9	-6	-5	N/A
12/31/2017	N/A	-10	N/A	-6	N/A
9/30/2017	N/A	-9	N/A	-7	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-7	N/A
12/31/2015	N/A	-5	N/A	-6	N/A
9/30/2015	N/A	-4	N/A	-6	N/A
6/30/2015	N/A	-2	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-6	N/A
9/30/2014	N/A	-6	N/A	-7	N/A
6/30/2014	N/A	-14	N/A	-6	N/A
3/31/2014	N/A	-9	N/A	-7	N/A
12/31/2013	N/A	-14	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NNVC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NNVC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NNVC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que NNVC no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que NNVC no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NNVC se prevé que sea elevada dentro de 3 años.

NanoViricides Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 38% to US$5.25

Recent updates

NanoViricides, Inc. Announces Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virusilling, Technology Platform Intending to Revolutionize Treatment of Viral Infections

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

New major risk - Financial position

NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2

Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development

Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2

New major risk - Revenue and earnings growth

Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides

Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well

Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

New major risk - Share price stability

Price target decreased by 38% to US$5.25

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

NanoViricides, Inc. announced delayed annual 10-K filing

NanoViricides, Inc. Reports Advantages Gained by Remdesivir Encapsulation

NanoViricides, Inc.(NYSEAM:NNVC) dropped from Russell Microcap Growth Index

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

New 90-day high: US$5.49

Consultant has left the company

New 90-day high: US$4.43

New 90-day low: US$3.08

Nanoviricides, Inc. Announces Board Changes

NanoViricides, Inc. announced delayed annual 10-K filing

New 90-day low: US$3.81

NanoViricides, Inc. Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

New 90-day low - US$5.57

NanoViricides, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento